Clinical data from patients with bladder pain syndrome support anakinra (IL1-RA) as a new, successful treatment option
Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections - has successfully completed the first part of a controlled clinical trial in patients with bladder pain syndrome (severe pain in the urinary bladder). The patients have been treated with anakinra, which is an Interleukin1 (IL-1) receptor antagonist (IL-1RA). The company can now announce that a significant proportion of the treated patients have responded positively to the treatment. Patients with bladder pain syndrome have severe pain, which is socially